litlas
Log inCreate account

Gilberto de Castro

Active 2005–2025

86
Papers
23,017
Citations
49
h-index
85
i10-index

Citations

Citations per year for Gilberto de Castro1926: 1 citations1928: 1 citations1971: 1 citations2001: 3 citations2003: 2 citations2007: 7 citations2008: 16 citations2009: 20 citations2010: 20 citations2011: 15 citations2012: 19 citations2013: 22 citations2014: 16 citations2015: 38 citations2016: 133 citations2017: 257 citations2018: 309 citations2019: 1,105 citations2020: 1,458 citations2021: 1,435 citations2022: 1,056 citations2023: 759 citations2024: 1,282 citations2025: 635 citations2026: 17 citations1927: no citations, so this year is not shown1929–1970: no citations, so these years are not shown1972–2000: no citations, so these years are not shown2002: no citations, so this year is not shown2004–2006: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,753 citing papers, 19.9% of this breakdownChina: 1,964 citing papers, 14.2% of this breakdownItaly: 849 citing papers, 6.1% of this breakdownJapan: 781 citing papers, 5.6% of this breakdownFrance: 675 citing papers, 4.9% of this breakdownUnited Kingdom: 667 citing papers, 4.8% of this breakdownGermany: 584 citing papers, 4.2% of this breakdownSpain: 562 citing papers, 4.1% of this breakdownCanada: 454 citing papers, 3.3% of this breakdownAustralia: 391 citing papers, 2.8% of this breakdownSouth Korea: 385 citing papers, 2.8% of this breakdownNetherlands: 347 citing papers, 2.5% of this breakdown
0%19.9%Other 24.8%

Institutions

Fields

  • Medicine82.4%
  • Biochemistry, Genetics and Molecular Biology11.5%
  • Immunology and Microbiology2.9%
  • Engineering0.6%
  • Computer Science0.5%
  • Dentistry0.4%
  • Other1.7%

Topics

  • Cancer Immunotherapy and Biomarkers18.5%
  • Lung Cancer Treatments and Mutations9.5%
  • Lung Cancer Research Studies6.1%
  • Lung Cancer Diagnosis and Treatment4.4%
  • Head and Neck Cancer Studies3.4%
  • Immunotherapy and Immune Responses3.2%
  • Other54.9%

Coauthors

All papers

Open in search
  1. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

    Authors: Barbara Burtness, Kevin J. Harrington, Richard Greil, Denis Soulières, Makoto Tahara, Gilberto de Castro, Amanda Psyrri, Neus Basté, Prakash Neupane, Åse Bratland, Thorsten Fuereder, Brett Hughes, Ricard Mesı́a, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Ruey‐Long Hong, René González Mendoza, Ananya Roy, Yayan Zhang, Burak Gümüşçü, Jonathan D. Cheng, Fan Jin, Danny Rischin, Guillermo Lerzo, Marcelo Tatangelo, Mirta Varela, Juan José Zarbá, Michael Boyer, Hui Gan, Bo Gao, Brett Hughes, Girish Mallesara, Danny Rischin, Anne L. Taylor, Martin Burian, Thorsten Fuereder, Richard Greil, Carlos H. Barrios, Dalvaro Oliveira de Castro Junior, Gilberto de Castro, Fábio Franke, Gustavo Girotto, Iane Pinto Figueiredo Lima, Ulisses Ribaldo Nicolau, Gustavo Dix Junqueira Pinto, Lucas Vieira dos Santos, Ana-Paula Victorino, Neil Chua, Félix Couture, Richard Gregg, Aaron R. Hansen, John Hilton, Joy McCarthy, Denis Soulières, Rodrigo Ascuí, Pablo Gonzalez, Luis J. Villanueva-Rivera, Marco Torregroza, Ángela R. Zambrano, Petra Holečková, Zdeněk Král, Bohuslav Melichar, Prausova Jana, Milan Vošmik, Maria Andersen, Niels Gyldenkerne, Hannes Jürgens, Kadri Putnik, Petri Reinikainen, Viktor Gruenwald, Simon Laban, Gerasimos Aravantinos, Ioannis Boukovinas, Vassilis Georgoulias, Amanda Psyrri, D.L.W. Kwong, Yousuf Al-Farhat, Tibor Csőszi, József Erfán, Geza Horvai, László Landherr, Éva Remenár, Ágnes Ruzsa, Judit Szota, Salem Billan, Iris Gluck, Orit Gutfeld, Aron Popovtzer, Marco Benasso, Simona Bui, Vittorio Ferrari, Lisa Licitra, Franco Nolè, Takashi Fujii, Yasushi Fujimoto, Nobuhiro Hanai, Hiroki Hara, Koji Matsumoto, Kenji Mitsugi and 119 more - The Lancet 2019 cited by 3,211

  2. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

    Authors: Tony Mok, Yi‐Long Wu, Iveta Kudaba, Dariusz M. Kowalski, Byoung Chul Cho, H.Z. Turna, Gilberto de Castro, Vichien Srimuninnimit, К. К. Лактионов, Igor Bondarenko, Kaoru Kubota, Gregory M. Lubiniecki, Jin Zhang, Debra Kush, Gilberto Lopes, Grigory Adamchuk, Myung‐Ju Ahn, Aurelia Alexandru, Özden Altundağ, Anna Alyasova, Orest Andrusenko, Keisuke Aoe, António Araújo, Osvaldo Rudy Aren, Oscar Arrieta Rodriguez, Touch Ativitavas, Oscar Avendaño, Fernando Barata, Carlos H. Barrios, Carlos Beato, Per Bergström, Daniel Betticher, Л. В. Болотина, Igor Bondarenko, Michiel Botha, Sayeuri Buddu, Christian Caglevic, Andrés F. Cardona, Gilberto de Castro, Hugo R. Castro, Filiz Çay Şenler, Carlos Alexandre Sydow Cerny, Alvydas Česas, Gee-Chen Chan, Jianhua Chang, Gongyan Chen, Xi Chen, Susanna Cheng, Ying Cheng, Nelly Cherciu, Chao‐Hua Chiu, Byoung Chul Cho, Saulius Cicėnas, Daniel Ciurescu, Graham Cohen, Marcos André Costa, Pongwut Danchaivijitr, Flávia De Angelis, Sérgio Jobim Azevedo, Mircea Dediu, Tsvetan Deliverski, Pedro Rafael Martins De Marchi, Flor de The Bustamante Valles, Zhenyu Ding, Boyan Doganov, Lydia Dreosti, Ricardo Duarte, Regina Edusma-Dy, S. A. Emelyanov, Mustafa Erman, Yun Fan, Luis Fein, Jifeng Feng, David Fenton, Gustavo dos Santos Fernandes, Carlos Gil Ferreira, Fábio Franke, H. Freitas, Yasuhito Fujisaka, Héctor Galindo, Christina Galvez, Doina Ganea, Nuno Gil, Gustavo Girotto, Erdem Göker, Tuncay Göksel, Gonzalo Gomez Aubin, Luis Gomez Wolff, Håkan Griph, Mahmut Gümüş, Jacqueline A. Hall, Gregory Hart, Libor Havel, Jianxing He, Yong He, Carlos Hernández Hernández, Venceslau Hespanhol, Tomonori Hirashima, Chung Man James Ho, Atsushi Horiike and 158 more - The Lancet 2019 cited by 3,334

  3. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

    Authors: Roy S. Herbst, Paul Baas, Dong‐Wan Kim, Enriqueta Felip, José Luis Perez‐Gracia, Ji‐Youn Han, Julian R. Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung‐Ju Ahn, Margarita Majem, Mary J. Fidler, Gilberto de Castro, Marcelo Garrido, Gregory M. Lubiniecki, Yue Shentu, Ellie Im, Marisa Dolled‐Filhart, Edward B. Garon - The Lancet 2015 cited by 6,537

  4. Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study

    Authors: Kevin J. Harrington, Barbara Burtness, Richard Greil, Denis Soulières, Makoto Tahara, Gilberto de Castro, Amanda Psyrri, Irene Braña, Neus Basté, Prakash Neupane, Åse Bratland, Thorsten Fuereder, Brett Hughes, Ricard Mesı́a, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Jianxin Lin, Burak Gümüşçü, Ramona F. Swaby, Danny Rischin - Journal of Clinical Oncology 2022 cited by 490

  5. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study

    Authors: Gilberto de Castro, Iveta Kudaba, Yi‐Long Wu, Gilberto Lopes, Dariusz M. Kowalski, H.Z. Turna, Christian Caglevic, Li Zhang, Bogusława Karaszewska, К. К. Лактионов, Vichien Srimuninnimit, Igor Bondarenko, Kaoru Kubota, Rinee Mukherjee, Jianxin Lin, Fabricio Souza, Tony Mok, Byoung Chul Cho - Journal of Clinical Oncology 2022 cited by 318

  6. First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

    Authors: Jean‐Charles Soria, Daniel S.W. Tan, Rita Chiari, Yi‐Long Wu, Luis Paz‐Ares, Juergen Wolf, Sarayut Lucien Geater, С. В. Орлов, Diego Cortinovis, Chong‐Jen Yu, Maximillian Hochmair, Alexis B. Cortot, Chun‐Ming Tsai, Denis Moro‐Sibilot, Rosario García Campelo, Tracey McCulloch, Paramita Sen, Margaret Dugan, Serafino Pantano, Fabrice Branle, Cristian Massacesi, Gilberto de Castro - The Lancet 2017 cited by 1,152

  7. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

    Authors: David Cameron, Martine Piccart, Richard D. Gelber, Marion Procter, Aron Goldhirsch, Evandro de Azambuja, Gilberto de Castro, Michael Untch, Ian Smith, Luca Gianni, José Baselga, N. Al-Sakaff, Sabine Lauer, Eleanor McFadden, Brian Leyland‐Jones, Richard H. Bell, Mitch Dowsett, Christian Jackisch - The Lancet 2017 cited by 1,041

  8. Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30

    Authors: Kim Cocks, Madeleine King, Galina Velikova, Gilberto de Castro, Marrissa Martyn St-James, Peter Fayers, Julia Brown - European Journal of Cancer 2012 cited by 565

  9. Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

    Authors: James Chih‐Hsin Yang, Dae Ho Lee, Jong‐Seok Lee, Yun Fan, Filippo de Marinis, Eiji Iwama, Takako Inoue, Jerónimo Rafael Rodríguez‐Cid, Li Zhang, Cheng‐Ta Yang, Emmanuel de la Mora Jimenez, Jianying Zhou, M. Pérol, Ki Hyeong Lee, David Vicente, Eiki Ichihara, Gregory J. Riely, Yiwen Luo, Diana Chirovsky, M. Catherine Pietanza, Niyati Bhagwati, Shun Lü, Michael Boyer, Rina Hui, Mark E. Wong, Andrew Mant, Phillip Parente, Thomas John, Sagun Parakh, Gilberto de Castro, Gustavo Werutsky, Sérgio Jobim Azevedo, Fábio Franke, Joilda Batista De Almeida Rego, Pedro Rafael Martins De Marchi, Gustavo Dix Junqueira, Fernanda Maris Peria, Leandro Brust, Parneet Cheema, Mark Doherty, Ambika Parmar, Ines B. Menjak, Natasha B. Leighl, Jason Agulnik, Shun Lü, Zhigang Han, Jiuwei Cui, Li Zhang, Ying Cheng, Gongyan Chen, Helong Zhang, Yu Yao, Chengping Hu, Qiming Wang, Xin Zhang, Yong Zhang, Jianying Zhou, Kejing Ying, Yun Fan, Yan Wang, Ziping Wang, Ji‐Feng Feng, Yingying Du, Lin Wu, Cheng Zhi Huang, Xiangdong Zhou, M. Pérol, Julien Dômont, Corinne Lamour, Julien Dutilh, Youssef Oulkhouir, Virginie Westeel, D. Carmier, Bruno Coudert, Aurélie Lagrange, Dominique Spaëth, Stanislas Ropert, Daniel C. Christoph, Jens Kern, Hans‐Georg Kopp, Frank Griesinger, Rainer Wiewrodt, Martin Wermke, Claas Wesseler, Annette Mueller, G Vogel, Victor Lee, Chung Man James Ho, Siu Hong Oscar Chan, Sing Hung Lo, Shi Feng Jonathan Nyaw, Yu Chung Jacky Li, Jair Bar, Maya Gottfried, Julia Dudnik, Alona Zer, Mor Moskovitz, Mirjana Wollner, Ofer Rotem, Sivan Shamai and 111 more - Journal of Clinical Oncology 2024 cited by 142

  10. Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study

    Authors: Luis Paz‐Ares, Óscar Juan, Giannis Mountzios, Enriqueta Felip, Niels Reinmuth, Filippo de Marinis, Nicolas Girard, Vipul M. Patel, Takayuki Takahama, Scott Owen, Douglas Reznick, Firas Badin, İrfan Çiçin, Sabeen Mekan, Riddhi Patel, Éric Zhang, Divyadeep Karumanchi, Marina Chiara Garassino, Elizabeth Ahern, Venessa Chin, Stephen Della‐Fiorentina, Kevin Jasas, Christos S. Karapetis, Jeremy Long, Louise Nott, Kenneth J. O’Byrne, Craig Underhill, Richard Greil, Maximilian J. Hochmair, Andreas Pircher, Wim Demey, Paul Germonpré, Elke Govaerts, Thierry Pieters, Reinier Wener, Alan A. Azambuja, Giuliano Santos Borges, Gilberto de Castro, Suellen Castro, Felipe Melo Cruz, Fábio Franke, Eduardo Silva, Parneet Cheema, Robert H. El-Maraghi, Swati Kulkarni, Rami Nassabein, Scott Owen, Clarisse Audigier-Valette, Jaafar Bennouna, C. Chouaïd, Alexis B. Cortot, S. Couraud, D. Debieuvre, Fabrice Denis, Patrick Dumont, Radj Gervais, Nicolas Girard, Etienne Giroux‐Leprieur, Florian Guisier, Sandrine Hiret, Henri Janicot, Corinne Lamour, J. Madelaine, M. Marcq, E. Pluquet, Jean Louis Pujol, Magali Ravoire, Marielle Sabatini, A. Vergnenègre, Sabine Bohnet, Martin Faehling, Melanie Janning, Eckart Laack, Niels Reinmuth, Achim Rittmeyer, Claas Wesseler, Sofia Baka, George Fountzilas, Panagiotis Katsaounis, Αthanasios Kotsakis, Ioannis Mountzios, Konstantinos Syrigos, Julia Dudnik, Fink Carmel, Ofer Merimsky, Hovav Nechushtan, Julia Sobolev, Franceso Agustoni, Anna Bettini, Matteo Brighenti, Giulio Cerea, Filippo de Marinis, Salvatore Grisanti, Francesco Grossi, Andrea Luciani, Evaristo Maiello, Héctor Soto Parrà, Pierfrancesco Tassone, Giuseppe Tonini, Yoko Agemi and 101 more - Journal of Clinical Oncology 2024 cited by 115

  11. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1–positive advanced non–small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies

    Authors: Kaname Nosaki, Hideo Saka, Yukio Hosomi, Paul Baas, Gilberto de Castro, Martin Reck, Yi‐Long Wu, Julie R. Brahmer, Enriqueta Felip, Takeshi Sawada, Kazuo Noguchi, Shi Rong Han, Bilal Piperdi, Debra Kush, Gilberto Lopes - Lung Cancer 2019 cited by 278

  12. Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Results From the CANOPY-1 Trial

    Authors: Daniel S.W. Tan, Enriqueta Felip, Gilberto de Castro, Benjamin Solomon, Alastair Greystoke, Byoung Chul Cho, Manuel Cobo, Tae Min Kim, Sandip Ganguly, Enric Carcereny, Luis Paz‐Ares, Jaafar Bennouna, Marina Chiara Garassino, Michael Schenker, Sang‐We Kim, Jan C. Brase, Denise Bury-Maynard, Vanessa Q. Passos, Stéphanie Deudon, Bharani Dharan, Yuanbo Song, Rafael Caparica, Bruce E. Johnson - Journal of Clinical Oncology 2023 cited by 74

  13. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC

    Authors: Tony Mok, G. Lopes, Byoung Chul Cho, Dariusz M. Kowalski, Kazuo Kasahara, Yi‐Long Wu, Gilberto de Castro, H.Z. Turna, Răzvan Cristescu, Deepti Aurora-Garg, Andrey Loboda, Jared Lunceford, Julie Kobie, Mark Ayers, M. Catherine Pietanza, Bilal Piperdi, Roy S. Herbst - Annals of Oncology 2023 cited by 71

  14. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients

    Authors: Evandro de Azambuja, Fátima Cardoso, Gilberto de Castro, Maria Antonietta Colozza, Max S. Mano, Virginie Durbecq, Christos Sotiriou, Denis Larsimont, M. Piccart-Gebhart, Marianne Paesmans - British Journal of Cancer 2007 cited by 958

  15. NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC

    Authors: Gilberto de Castro, Naiyer A. Rizvi, Peter Schmid, Konstantinos Syrigos, Claudio Martín, Nobuyuki Yamamoto, Ying Cheng, Vladimir Moiseyenko, Yvonne Summers, Ihor Vynnychenko, Sung Yong Lee, Maciej Bryl, Alona Zer, Mustafa Erman, Constanta Timcheva, Rajiv Raja, Kirsha Naicker, Urban Scheuring, Jill Walker, Helen Mann, Vikram K. Chand, Tony Mok - Journal of Thoracic Oncology 2022 cited by 72

  16. OA01.04 Five-Year Survival in Patients with ES-SCLC Treated with Atezolizumab in IMpower133: Imbrella a Extension Study Results

    Authors: Stephen V. Liu, Rafał Dziadziuszko, Shunichi Sugawara, Steven Kao, Maximilian J. Hochmair, Florian Huemer, Gilberto de Castro, Libor Havel, R.B. Caro, G Losonczy, J.-S. Lee, D. Kowalski, Zoran Andrić, Raffaele Califano, Andrea Veatch, Gregory J. Gerstner, Marta Batus, S. Morris, Manika Kaul, M. Siddiqui, H. Li, W. Zhang, Barzin Y. Nabet, Martin Reck - Journal of Thoracic Oncology 2023 cited by 36

  17. Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study

    Authors: Martin Reck, Rafał Dziadziuszko, Shunichi Sugawara, Steven Kao, Maximilian J. Hochmair, Florian Huemer, Gilberto de Castro, Libor Havel, Reyes Bernabé Caro, György Losonczy, Jong Seok Lee, Dariusz M. Kowalski, Zoran Andric, Raffaele Califano, Andrea Veatch, Gregory J. Gerstner, Marta Batus, Stefanie Morris, Monika Kaul, Vaikunth Cuchelkar, Huafei Li, Bradford J. Danner, Barzin Y. Nabet, Stephen V. Liu - Lung Cancer 2024 cited by 67

  18. Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042

    Authors: Aaron S. Mansfield, Roy S. Herbst, Gilberto de Castro, Rina Hui, Nir Peled, Dong‐Wan Kim, Silvia Novello, Miyako Satouchi, Yi‐Long Wu, Edward B. Garon, Martin Reck, Andrew Robinson, Ayman Samkari, Bilal Piperdi, Victoria Ebiana, Jianxin Lin, Tony Mok - JTO Clinical and Research Reports 2021 cited by 82

  19. Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort

    Authors: Rafał Dziadziuszko, Tony Mok, Solange Peters, Ji‐Youn Han, Jorge Alatorre-Alexander, Natasha B. Leighl, Virote Sriuranpong, M. Pérol, Gilberto de Castro, Ernest Nadal, Filippo de Marinis, Osvaldo Arén Frontera, Daniel S.W. Tan, Dae Ho Lee, Hye Ryun Kim, Mark Yan, Todd Riehl, Erica Schleifman, Sarah Paul, Simonetta Mocci, Rajesh Patel, Zoe J. Assaf, David S. Shames, Michael S. Mathisen, Shirish M. Gadgeel - Journal of Thoracic Oncology 2021 cited by 61

  20. A prospective cross-sectional study estimated glomerular filtration rate from creatinine and cystatin C in adults with solid tumors

    Authors: Verônica T. Costa e Silva, Luiz Antonio Gil, Lesley A. Inker, Renato A. Caires, Elerson Costalonga, George Barbério Coura-Filho, Marcelo Tatit Sapienza, Gilberto de Castro, Maria D.P. Estevez-Diz, Dirce Maria Trevisan Zanetta, Leila Antonângelo, Lia Marçal, Hocine Tighiouart, Shiyuan Miao, Paul Mathew, Andrew S. Levey, Emmanuel A. Burdmann - Kidney International 2022 cited by 59

  21. Meta-omics analysis indicates the saliva microbiome and its proteins associated with the prognosis of oral cancer patients

    Authors: Daniela C. Granato, Leandro Xavier Neves, Luciana D. Trino, Carolina Moretto Carnielli, Ariane F. Busso‐Lopes, Sami Yokoo, Bianca Alves Pauletti, Romênia R. Domingues, JAMILE DE OLIVEIRA SÁ, Gabriella Persinoti, Maria Paula Paixão, César Rivera, Fábio Malta de Sá Patroni, Geizecler Tommazetto, Alan Roger Santos‐Silva, Márcio Ajudarte Lopes, Gilberto de Castro, Thaís Bianca Brandão, Ana Carolina Prado Ribeiro, Fábio M. Squina, Guilherme P. Telles, Adriana Franco Paes Leme - Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 2021 cited by 51

  22. Combining discovery and targeted proteomics reveals a prognostic signature in oral cancer

    Authors: Carolina Moretto Carnielli, Carolina Carneiro Soares Macedo, Tatiane De Rossi, Daniela C. Granato, César Rivera, Romênia R. Domingues, Bianca Alves Pauletti, Sami Yokoo, Henry Heberle, Ariane F. Busso‐Lopes, Nilva K. Cervigne, Íris Sawazaki‐Calone, Gabriela Vaz Meirelles, Fábio Albuquerque Marchi, Guilherme P. Telles, Rosane Minghim, Ana Carolina Prado Ribeiro, Thaís Bianca Brandão, Gilberto de Castro, Wilfredo Alejandro González‐Arriagada, Alexandre F. Gomes, Fabio Penteado, Alan Roger Santos‐Silva, Márcio Ajudarte Lopes, Priscila Campioni Rodrigues, Elias Sundquist, Tuula Salo, Sabrina Daniela da Silva, Moulay A. Alaoui‐Jamali, Edgard Graner, Jay W. Fox, Ricardo Della Coletta, Adriana Franco Paes Leme - Nature Communications 2018 cited by 198

  23. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

    Authors: Jean-Pascal H. Machiels, Robert I. Haddad, Jérôme Fayette, Lisa Licitra, Makoto Tahara, Jan B. Vermorken, Paul M. Clément, Thomas Gauler, Didier Cupissol, Juan J. Grau, J. Guigay, Francesco Caponigro, Gilberto de Castro, Luciano de Souza Viana, Ulrich Keilholz, Joseph M del Campo, Xiuyu Julie Cong, E. Ehrnrooth, Ezra E.W. Cohen - The Lancet Oncology 2015 cited by 392

  24. LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042

    Authors: Roy S. Herbst, Gilberto Lopes, Dariusz M. Kowalski, Kazuo Kasahara, Yuanqiang Wu, Gilberto de Castro, Byoung Chul Cho, H.Z. Turna, Răzvan Cristescu, Deepti Aurora-Garg, Jared Lunceford, Julie Kobie, Mark Ayers, M. Catherine Pietanza, Bilal Piperdi, Tony Mok - Annals of Oncology 2019 cited by 92